Medicare forces insurers to stop steering seniors toward expensive drugs

What it does

This bill requires Medicare prescription drug plans (Part D) to include all generic drugs and at least one biosimilar that cost less than their brand-name equivalents, and to place them in lower cost-sharing tiers with copayments at least $20 cheaper than brand drugs. Starting in 2028, insurers cannot use prior authorization or step therapy to discourage seniors from choosing these cheaper alternatives.

Why we flagged it

The bill's core function is to mandate formulary inclusion and favorable cost-sharing for generic and biosimilar drugs in Medicare Part D plans, directly addressing senior medication affordability rather than creating new programs or revenue mechanisms.

What the text implies

• Insurers may respond by raising copayments on brand drugs or narrowing formularies in other ways to offset margin pressure, potentially shifting costs to seniors using specialty or brand medications.
• The bill's reliance on 'wholesale acquisition cost' as the pricing benchmark may create gaming opportunities if manufacturers manipulate WAC pricing, and the Secretary's discretion to define cost thresholds introduces regulatory uncertainty.
• Pharmacy benefit managers (PBMs) may face reduced rebate revenue from brand manufacturers, potentially increasing administrative fees or reducing network pharmacy reimbursements, with downstream effects on pharmacy access.
• The 2028 implementation date gives insurers time to restructure benefit designs, and the bill's exemptions for deductibles and specialty tiers may allow plans to maintain high out-of-pocket costs for certain drug categories.

Who it affects

Seniors gain direct access to lower-cost generic and biosimilar medications with reduced cost-sharing barriers, lowering out-of-pocket drug expenses. The bill removes insurer incentives to steer patients toward expensive brand drugs, improving affordability and medication access for a vulnerable population.

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• seniors (reduced out-of-pocket costs)
• Medicare program (potential savings from lower-cost drug utilization)

Named in the bill

Medicare Part D, PDP sponsors, Medicare Advantage organizations, FDA, HHS Secretary, generic drug manufacturers, biosimilar manufacturers, pharmacy benefit managers, Costco (direct reference in mapped stocks)

Where it stands

2 cosponsors: 2 Democrats.

• Apr 16, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Apr 16, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $5,722,990 in lobbying spend. A filing names 39 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

James Lankford, the sponsor, reported $368,500 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.